Investigational drug · Phase 2
ICP-723
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion, Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "ICP-723"
First trial start
2020
Sep 27, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ICP-723", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors Harboring NTRK Fusion
- Primary Central Nervous System Tumors Harboring NTRK Fusion
- Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ICP-723" as an intervention, largest first.
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT04685226 · 310 participants (planned) · Start Sep 27, 2020 · Primary completion Jan 25, 2028
Drug: ICP-723 · For: Solid Tumors
Sites: Hefei, China; Beijing, China; Guangzhou, China · 24 sites in all
- Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System TumorsRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT05745623 · 70 participants (planned) · Start Dec 27, 2022 · Primary completion Dec 25, 2027
Drug: ICP-723 · For: Advanced Solid Tumors Harboring NTRK Fusion; Primary Central Nervous System Tumors Harboring NTRK Fusion
Sites: Guangzhou, China
- Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid TumorsStatus unknown
InnoCare Pharma Inc.Industry
NCT05537987 · 30 participants (planned) · Start Jul 30, 2021 · Primary completion Nov 2023
Drug: ICP-723 · For: Advanced Solid Tumors
Sites: Kansas City, Kansas; New York, New York; Tacoma, Washington
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.